FilingFirehose · free AI preview
Xeris Biopharma Holdings, Inc.
XERS · AI-generated SEC analysis preview · refreshes when data changes
⚠️ Red flag 8-Ks: 1
Types: Officer Departure
Xeris Biopharma Holdings (XERS) reported one officer departure in a Section 5.02 8-K filing on April 21, 2026, with no cyber incidents detected in the past 90 days. The departure itself raises questions about leadership stability and potential operational impact that warrant context from the company's broader capital structure and financing history. The full $49 Report adds dilution risk scoring, detailed 8-K context around the departure timing, 12-month financing trajectory, and AI-detected risk signals across executive transitions and cash runway metrics.
Want the full 5-section $49 Report on XERS?
Dilution risk score · 12 months of 8-K context · financing history · AI risk signals · bottom-line framing. Delivered in ~5 minutes.
See a real sample report →
This preview was AI-generated from FilingFirehose's SEC EDGAR ingestion pipeline.
Not investment advice. Verify all claims against original filings.